Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$68.62+2.26 (+3.41%)
Close on Nov 11, 2026Market cap $10.21BP/E –Yield 0.00%
Vaxcyte cash
Cash and short-term investments held at the end of each period.
Vaxcyte's cash was $1.29B at Sep 30, 2026. For fiscal 2025 it was $1.56B, down 10.7% from the year before. The highest annual figure on record is $1.75B in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | -10.7% |
| FY2024 | Dec 31, 2024 | $1.75B | +61.9% |
| FY2023 | Dec 31, 2023 | $1.08B | +15.9% |
| FY2022 | Dec 31, 2022 | $932.25M | +277.7% |
| FY2021 | Dec 31, 2021 | $246.84M | -36.1% |
| FY2020 | Dec 31, 2020 | $386.20M | +554.8% |
| FY2019 | Dec 31, 2019 | $58.98M | -10.8% |
| FY2018 | Dec 31, 2018 | $66.09M | +82.9% |
| FY2017 | Dec 31, 2017 | $36.14M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.29B | -24.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.49B | -10.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.74B | +3.9% |
| Q4 FY2025 | Dec 31, 2025 | $1.56B | -10.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.71B | -21.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.66B | +14.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.67B | +12.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.75B | +61.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.18B | +72.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.45B | +12.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.49B | +80.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.08B | +15.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.27B | +248.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.29B | +262.4% |
| Q1 FY2023 | Mar 31, 2023 | $822.91M | +145.3% |
| Q4 FY2022 | Dec 31, 2022 | $932.25M | +277.7% |
| Q3 FY2022 | Sep 30, 2022 | $363.10M | +29.9% |
| Q2 FY2022 | Jun 30, 2022 | $355.37M | +21.3% |
| Q1 FY2022 | Mar 31, 2022 | $335.51M | +4.2% |
| Q4 FY2021 | Dec 31, 2021 | $246.84M | -36.1% |
| Q3 FY2021 | Sep 30, 2021 | $279.45M | -29.6% |
| Q2 FY2021 | Jun 30, 2021 | $292.99M | -28.5% |
| Q1 FY2021 | Mar 31, 2021 | $321.99M | +108.0% |
| Q4 FY2020 | Dec 31, 2020 | $386.20M | +554.8% |
| Q3 FY2020 | Sep 30, 2020 | $397.05M | +1091.5% |
| Q2 FY2020 | Jun 30, 2020 | $410.05M | +865.4% |
| Q1 FY2020 | Mar 31, 2020 | $154.79M | +134.2% |
| Q4 FY2019 | Dec 31, 2019 | $58.98M | +63.2% |
| Q3 FY2019 | Sep 30, 2019 | $33.32M | – |
| Q2 FY2019 | Jun 30, 2019 | $42.47M | – |
| Q4 FY2018 | Dec 31, 2018 | $66.09M | – |
| Q4 FY2017 | Dec 31, 2017 | $36.14M | – |
See a number that looks wrong?